Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation (NCT02682199) | Clinical Trial Compass
CompletedNot Applicable
Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation
United States100 participantsStarted 2015-10
Plain-language summary
The goal of this prospective observational study is to investigate whether whole brain radiation leads to measurable xerostomia from parotid gland toxicity.
Who can participate
Age range18 Years – 99 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients to be treated with whole brain radiation in 10-15 fractions to a total dose of 25-37.5 Gy for a diagnosis of brain metastases from any disease site or as prophylaxis in the treatment of potentially subclinical intracranial disease (e.g. from small cell lung cancer).
* Has not had prior radiation that would have exposed the parotids to a significant (estimated \>10 Gy mean parotid dose) level of radiation within the past one year. Patients receiving prior stereotactic radiosurgery for brain metastasis are eligible for inclusion in this trial as this form of radiation is highly conformal and exposes the parotids to minimal (estimated \<1 Gy) radiation.
* Greater than or equal to 18 years of age (no upper age limit).
* Informed consent obtained.
Exclusion Criteria:
* Patients receiving whole brain radiation without the use of a CT-based planning simulation.
* Patients who are on medications known to cause dry mouth, such as anticholinergics.
* Physically unable to communicate by paper or phone to complete the study survey.
* Prisoners.